Sun-Novo(SH:688621) Orient Securities·2025-04-15 14:46Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company achieved a revenue of 1.078 billion yuan in 2024, representing a year-on-year growth of 15.7%, while the net profit attributable to the parent company decreased by 3.98% to 177 million yuan [9] - New orders continued to grow rapidly, with a total of 1.786 billion yuan in new orders signed in 2024, an increase of 18.74% year-on-year, and a backlog of 3.273 billion yuan, up 27.57% year-on-year, providing a solid foundation for future growth [9] - The company emphasizes innovation in drug research and development, with R&D expenses increasing by 39% to 172 million yuan in 2024, accounting for 15.9% of revenue [9] Financial Forecast and Investment Recommendations - The forecast for earnings per share (EPS) has been adjusted downwards to 1.98 yuan for 2025 and 2.36 yuan for 2026, with a new estimate of 2.95 yuan for 2027 [2] - The reasonable valuation level for the company is set at a price-to-earnings (PE) ratio of 29 times for 2025, corresponding to a target price of 57.42 yuan [2] Financial Information Summary - The company's revenue is projected to grow from 1.078 billion yuan in 2024 to 1.753 billion yuan in 2027, with respective year-on-year growth rates of 15.7%, 22.0%, 15.6%, and 15.3% [4] - The gross margin is expected to stabilize around 50.5% to 50.8% from 2025 to 2027, while the net profit margin is projected to improve from 16.8% in 2025 to 18.9% in 2027 [4] - The return on equity (ROE) is forecasted to increase from 18.4% in 2025 to 19.6% in 2027 [4]